Evidence map›Paper›PMID 42015519›Full record

ArticleClinical infectious diseases : an official publication of the Infectious Diseases Society of America2026

Fosmanogepix Treatment for Coccidioidomycosis Under an Expanded Access Program.

Stuart H Cohen, Paul Allyn, Felicia C Chow, Jennifer Rathe, Deepa D Nanayakkara, Gerald Hutfles, Tara Vijayan, Ethan A Smith, Christopher F Saling, Dan Ilges and 2 more

Registry-linked trialAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06433128 (Expanded Access to Fosmanogepix for Patients With Serious or Life-threatening Invasive Fungal Infections Who Have no Other Treatment Options), which is not on this map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06433128 availablenot on this map

Expanded Access to Fosmanogepix for Patients With Serious or Life-threatening Invasive Fungal Infections Who Have no Other Treatment Options

Typeexpanded_accessSponsorBasilea PharmaceuticaConditionsInvasive Fungal InfectionsArmsFosmanogepix solution for infusion, Fosmanogepix 400 mg tablets
3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Stuart H CohenDepartment of Internal Medicine, Division of Infectious Diseases, University of California Davis Medical Center, Sacramento, California, USA.ORCID 0009-0001-0043-0508
Paul AllynDepartment of Internal Medicine, Division of Infectious Diseases, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, California, USA.ORCID 0000-0002-3659-8732
Felicia C ChowUniversity of California SanFrancisco, San Francisco, California, USA.
Jennifer RatheDivision of Infectious Diseases, George Washington University School of Medicine and Health Sciences, Washington D. C., USA.ORCID 0000-0001-7268-5131
Deepa D NanayakkaraDepartment of Internal Medicine, Division of Infectious Diseases, City of Hope, Duarte, California, USA.
Gerald HutflesDepartment of Internal Medicine, Division of Infectious Diseases, Kaiser Permanente Northwest, Portland, Oregon, USA.ORCID 0000-0002-7237-279X
Tara VijayanDepartment of Internal Medicine, Division of Infectious Diseases, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, California, USA.ORCID 0000-0003-1141-8261
Ethan A SmithDepartment of Internal Medicine, Division of Infectious Diseases, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, California, USA.ORCID 0009-0002-9186-0059
Christopher F SalingDepartment of Infectious Disease, Mayo Clinic Arizona, Phoenix, Arizona, USA.
Dan IlgesDepartment of Pharmacy, Mayo Clinic Arizona, Pheonix, Arizona, USA.ORCID 0000-0003-0778-3901
Haran T SchlammHTS Pharma, San Diego, California, USA.
George R ThompsonDepartment of Internal Medicine, Division of Infectious Diseases, University of California Davis Medical Center, Sacramento, California, USA.ORCID 0000-0001-8518-5750

Funding

Basilea Pharmaceutica International Ltd
6 · The paper itself

Abstract

Coccidioidomycosis is an invasive fungal infection that can disseminate and cause severe disease. Fosmanogepix ("gepix"), a first-in-class antifungal available via expanded access (NCT06433128), was successful in 8/11 patients (meningitis, 6/8 [75%]; nonmeningeal dissemination, 2/3 [66%]) and was well tolerated for a median treatment duration of 208 days.

Indexed as

Antifungal AgentsCoccidioidomycosisAdultAgedClinical Trials as TopicFemaleHumansMaleMiddle AgedTreatment OutcomeYoung AdultAntifungal Agentsantifungalcoccidioidomycosisexpanded access programfosmanogepix

Identifiers

PMID42015519
PMCPMC13644858

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.